Personalized mRNA Melanoma Vaccine Reports Positive Phase 3 Results
Merck and Moderna say intismeran plus pembrolizumab improved two measures of melanoma recurrence after surgery, but the full Phase 3 data are not yet public.
Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 21, 2026.
Merck and Moderna have reported a positive Phase 3 result for intismeran autogene, a personalized mRNA treatment vaccine, combined with pembrolizumab after surgery for high-risk melanoma. The companies say the combination improved recurrence-free survival and distant metastasis-free survival compared with pembrolizumab alone. However, this is a topline company announcement, not a complete presentation or peer-reviewed publication of the Phase 3 data.
The result is encouraging because the trial met its primary endpoint and a key secondary endpoint. It does not yet tell us the size of the benefit, the detailed safety findings, whether overall survival improved, or how regulators will assess the treatment.
Article note: This story reflects the topline information available on August 21, 2026. It should be materially updated when the complete INTerpath-001 Phase 3 results are presented at a medical meeting or published in a peer-reviewed journal.
What did the Phase 3 trial report?
INTerpath-001 is a randomized Phase 3 trial in people with stage IIB, IIC, III, or IV cutaneous melanoma whose tumors had been completely removed by surgery. Participants had not previously received systemic treatment for melanoma. The study compared intismeran plus pembrolizumab with pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of the cancer returning.
At a prespecified interim analysis, Merck and Moderna reported that the combination produced statistically significant and clinically meaningful improvements in:
- Recurrence-free survival: the length of time after treatment without melanoma returning or death.
- Distant metastasis-free survival: the length of time without melanoma spreading to a distant part of the body or death.
The announcement did not include hazard ratios, absolute event rates, confidence intervals, follow-up duration, subgroup results, or detailed safety data. It also did not report an overall-survival result. Without those numbers, readers cannot yet judge the magnitude or precision of the Phase 3 benefit.
Is this a vaccine that prevents melanoma?
No. Intismeran is an investigational therapeutic cancer vaccine for people already diagnosed with melanoma. It is not a preventive vaccine for healthy people, and it was tested here after a patient’s melanoma had been surgically removed.
The National Cancer Institute explains that cancer treatment vaccines aim to help the immune system recognize and attack cancer cells. That is different from preventive vaccines, such as those designed to prevent infections that can cause cancer.
Intismeran is individualized from features of each patient’s tumor. Researchers sequence tumor and normal tissue, identify mutations that could produce tumor-specific proteins called neoantigens, and select up to 34 neoantigens for an mRNA therapy made for that patient. The goal is to train T cells to recognize cells carrying those targets.
Pembrolizumab, sold by Merck as Keytruda, is an anti-PD-1 checkpoint inhibitor. It blocks a signal that can restrain T-cell activity. The proposed combination therefore uses one therapy to show the immune system personalized tumor targets and another to help immune cells remain active against them.
What are Moderna’s and Merck’s roles?
The two medicines do different jobs in the combination, while the intismeran development program itself is shared by both companies.
| Comparison | Moderna and intismeran | Merck and pembrolizumab |
|---|---|---|
| Company role | Moderna contributes its mRNA design and manufacturing platform to produce the individualized therapy. | Merck contributes pembrolizumab and oncology clinical-development expertise. |
| Therapy | Intismeran autogene, also known as V940 or mRNA-4157. | Pembrolizumab, marketed as Keytruda. |
| Mechanism | mRNA encodes selected tumor neoantigens with the aim of prompting a tumor-specific T-cell response. | An anti-PD-1 antibody releases an immune checkpoint that can limit T-cell activity. |
| Personalization | Each therapy is designed from the mutations identified in one patient’s tumor and can encode up to 34 neoantigens. | The antibody itself is not custom-made for each patient, although treatment eligibility depends on the cancer and clinical setting. |
| Regulatory status in this use | Intismeran is investigational and is not approved by the US Food and Drug Administration. | Pembrolizumab is approved for multiple cancer indications, including certain melanoma settings, but the intismeran-pembrolizumab combination remains investigational. |
| Development responsibility | Merck and Moderna jointly develop intismeran and the combination program. | Merck and Moderna jointly develop intismeran and the combination program. |
The table describes the companies’ stated development roles and the therapies’ mechanisms. It does not establish that the investigational combination is safe, effective, or approved for an individual patient.
What earlier evidence supports the result?
The Phase 3 program followed the randomized Phase 2b KEYNOTE-942 study in 157 people with completely resected, high-risk stage III or IV melanoma. A peer-reviewed five-year follow-up in the Journal of Clinical Oncology reported sustained improvements in recurrence-free and distant metastasis-free survival with intismeran plus pembrolizumab compared with pembrolizumab alone. The five-year analyses were descriptive, and the study was much smaller than INTerpath-001.
Those earlier results strengthen the rationale for the Phase 3 trial, but they do not substitute for its complete data. The Phase 3 population also included stage IIB and IIC disease, so the new dataset will be important for understanding outcomes across the enrolled stages.
What remains unknown?
Several questions cannot be answered from the topline announcement:
- How large was the benefit? No numerical Phase 3 efficacy estimates have been released.
- What were the detailed safety results? The companies said the combination’s safety profile was consistent with earlier studies, but adverse-event rates and discontinuations are not yet available.
- Did people live longer? No overall-survival result was reported.
- Did every subgroup benefit similarly? Results by stage, age, tumor characteristics, and other factors have not been presented.
- How will the evidence hold up to external review? The Phase 3 findings have not yet been presented in full, peer reviewed, or evaluated through a completed regulatory review.
- What would treatment require in practice? Manufacturing time, access, cost, and real-world delivery have not been established for an approved product because intismeran remains investigational.
What does this mean for people with melanoma now?
The result is an important late-stage signal for a personalized cancer treatment, not a treatment option that people can request as routine care today. It applies to the specific trial setting of completely resected, high-risk cutaneous melanoma and should not be generalized to other cancers or to melanoma prevention.
People being treated for melanoma should not change care based on a press release. Decisions about adjuvant therapy depend on melanoma stage, prior treatment, recurrence risk, approved options, and individual health factors. The complete Phase 3 presentation, peer review, and regulatory assessment will provide the evidence needed to understand where this combination may fit.
The bottom line
INTerpath-001 is a positive company-reported Phase 3 topline result for intismeran plus pembrolizumab after surgery for high-risk melanoma. It supports the possibility that a treatment personalized to a tumor’s mutations can add benefit to checkpoint immunotherapy. It does not show that cancer recurrence was eliminated, and it does not establish benefit in other cancers.
The next meaningful milestone is release of the full Phase 3 dataset, including numerical efficacy, detailed safety, follow-up, subgroup, and overall-survival information, followed by peer and regulatory review.
